The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety
Open accessAbstract
T lymphocytes expressing a chimeric antigen receptor (CAR) targeting the CD19 antigen (CAR.19) may be of value for the therapy of B-cell malignancies. Because the in vivo survival, expansion and anti-lymphoma activity of CAR.19+ T cells remain suboptimal even when the CAR contains a CD28 costimulatory endodomain, we generated a novel construct that also incorporates the interleukin-15 (IL-15) gene and an inducible caspase-9-based suicide gene (iC9/CAR.19/IL-15). We found that compared with CAR.19+ T cells, iC9/CAR.19/IL-15+ T cells had: (1) greater numeric expansion upon antigen stimulation (10-fold greater expansion in vitro, and 3- to 15-fold greater expansion in vivo) and reduced cell death rate (Annexin-V+/7-AAD+ cells 10±6% for iC9/CAR.19/IL-15+ T cells and 32±19% for CAR.19+ T cells); (2) reduced expression of the programmed death 1 (PD-1) receptor upon antigen stimulation (PD-1+ cells <15% for iC9/CAR.19/IL-15+ T cells versus >40% for CAR.19+ T cells); and (3) improved antitumor effects in vivo (from 4.7- to 5.4-fold reduced tumor growth). In addition, iC9/CAR.19/IL-15+ T cells were efficiently eliminated upon pharmacologic activation of the suicide gene. In summary, this strategy safely increases the anti-lymphoma/leukemia effects of CAR.19-redirected T lymphocytes and may be a useful approach for treatment of patients with B-cell malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680
Immunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A., & Dudley, M. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2355 · Cited by 1,659
Eshhar, Z., Waks, T., Gross, G., & Schindler, D. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.720 · Cited by 1,658
Dudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,639
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314
A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., White, D. E., Wunderlich, J. R., Canevari, S., Rogers-Freezer, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1183 · Cited by 1,254
Milone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197
Pule, M. A., Savoldo, B., Myers, G. D., Rossig, C., Russell, H. V., Dotti, G., Huls, M. H., Liu, E., Gee, A. P., Mei, Z., et al. (2008) · Nature Medicine · doi:10.1038/nm.1882 · Cited by 1,195
Self-citationHuman T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor
Maher, J., Brentjens, R. J., Gunset, G., Rivière, I., & Sadelain, M. (2002) · Nature Biotechnology · doi:10.1038/nbt0102-70 · Cited by 1,034
Lamers, C. H. J., Sleijfer, S., Vulto, A. G., Kruit, W. H. J., Kliffen, M., Debets, R., Gratama, J. W., Stoter, G., & Oosterwijk, E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9964 · Cited by 915
Carpenito, C., Milone, M. C., Hassan, R., Simonet, J. C., Lakhal, M., Suhoski, M. M., Varela-Rohena, A., Haines, K. M., Heitjan, D. F., Albelda, S. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813101106 · Cited by 888
Imai, C., Mihara, K., Andreansky, M., Nicholson, I. C., Pui, C.-H., Geiger, T. L., & Campana, D. (2004) · Leukemia · doi:10.1038/sj.leu.2403302 · Cited by 840
DIVERSE FUNCTIONS OF IL-2, IL-15, AND IL-7 IN LYMPHOID HOMEOSTASIS
Ma, A., Koka, R., & Burkett, P. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090727 · Cited by 829
An inducible caspase 9 safety switch for T-cell therapy
Straathof, K. C., Pulè, M. A., Yotnda, P., Dotti, G., Vanin, E. F., Brenner, M. K., Heslop, H. E., Spencer, D. M., & Rooney, C. M. (2005) · Blood · doi:10.1182/blood-2004-11-4564 · Cited by 742
Self-citationTill, B. G., Jensen, M. C., Wang, J., Chen, E. Y., Wood, B. L., Greisman, H. A., Qian, X., James, S. E., Raubitschek, A., Forman, S. J., et al. (2008) · Blood · doi:10.1182/blood-2007-12-128843 · Cited by 722
Brentjens, R. J., Latouche, J.-B., Santos, E., Marti, F., Gong, M. C., Lyddane, C., King, P. D., Larson, S., Weiss, M., Rivière, I., et al. (2003) · Nature Medicine · doi:10.1038/nm827 · Cited by 669
Adoptive-cell-transfer therapy for the treatment of patients with cancer
Dudley, M. E., & Rosenberg, S. A. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1167 · Cited by 660
Urbani, S., Amadei, B., Tola, D., Massari, M., Schivazappa, S., Missale, G., & Ferrari, C. (2006) · Journal of Virology · doi:10.1128/jvi.01177-06 · Cited by 588
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8 + T Cells
Klebanoff, C. A., Finkelstein, S. E., Surman, D. R., Lichtman, M. K., Gattinoni, L., Theoret, M. R., Grewal, N., Spiess, P. J., Antony, P. A., Palmer, D. C., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307298101 · Cited by 577
Finney, H. M., Lawson, A. D. G., Bebbington, C. R., & Weir, A. N. C. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.6.2791 · Cited by 546
Di Stasi, A., De Angelis, B., Rooney, C. M., Zhang, L., Mahendravada, A., Foster, A. E., Heslop, H. E., Brenner, M. K., Dotti, G., & Savoldo, B. (2009) · Blood · doi:10.1182/blood-2009-03-209650 · Cited by 533
Self-citationPulè, M. A., Straathof, K. C., Dotti, G., Heslop, H. E., Rooney, C. M., & Brenner, M. K. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.04.016 · Cited by 487
Self-citationKowolik, C. M., Topp, M. S., Gonzalez, S., Pfeiffer, T., Olivares, S., Gonzalez, N., Smith, D. D., Forman, S. J., Jensen, M. C., & Cooper, L. J. N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0160 · Cited by 487
The promise and potential pitfalls of chimeric antigen receptors
Sadelain, M., Brentjens, R., & Rivière, I. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.02.009 · Cited by 467
Waldmann, T. (2001) · Immunity · doi:10.1016/s1074-7613(09)00091-0 · Cited by 434
PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model
Zhang, L., Gajewski, T. F., & Kline, J. (2009) · Blood · doi:10.1182/blood-2009-03-206672 · Cited by 411
Brentjens, R., Yeh, R., Bernal, Y., Riviere, I., & Sadelain, M. (2010) · Molecular Therapy · doi:10.1038/mt.2010.31 · Cited by 377
Zhao, Y., Wang, Q. J., Yang, S., Kochenderfer, J. N., Zheng, Z., Zhong, X., Sadelain, M., Eshhar, Z., Rosenberg, S. A., & Morgan, R. A. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900447 · Cited by 293
Vera, J., Savoldo, B., Vigouroux, S., Biagi, E., Pule, M., Rossig, C., Wu, J., Heslop, H. E., Rooney, C. M., Brenner, M. K., et al. (2006) · Blood · doi:10.1182/blood-2006-04-017061 · Cited by 275
Self-citationMumprecht, S., Schürch, C., Schwaller, J., Solenthaler, M., & Ochsenbein, A. F. (2009) · Blood · doi:10.1182/blood-2008-09-179697 · Cited by 267
Cooper, L. J. N., Topp, M. S., Serrano, L. M., Gonzalez, S., Chang, W.-C., Naranjo, A., Wright, C., Popplewell, L., Raubitschek, A., Forman, S. J., et al. (2003) · Blood · doi:10.1182/blood-2002-07-1989 · Cited by 248
Safety and immunologic effects of IL-15 administration in nonhuman primates
Berger, C., Berger, M., Hackman, R. C., Gough, M., Elliott, C., Jensen, M. C., & Riddell, S. R. (2009) · Blood · doi:10.1182/blood-2008-12-189266 · Cited by 244
Savoldo, B., Rooney, C. M., Di Stasi, A., Abken, H., Hombach, A., Foster, A. E., Zhang, L., Heslop, H. E., Brenner, M. K., & Dotti, G. (2007) · Blood · doi:10.1182/blood-2006-11-059139 · Cited by 234
Self-citationWang, J., Jensen, M., Lin, Y., Sui, X., Chen, E., Lindgren, C. G., Till, B., Raubitschek, A., Forman, S. J., Qian, X., et al. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.028 · Cited by 213
Tey, S.-K., Dotti, G., Rooney, C. M., Heslop, H. E., & Brenner, M. K. (2007) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2007.04.005 · Cited by 204
Self-citationTammana, S., Huang, X., Wong, M., Milone, M. C., Ma, L., Levine, B. L., June, C. H., Wagner, J. E., Blazar, B. R., & Zhou, X. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.122 · Cited by 165
Quintarelli, C., Vera, J., Savoldo, B., Giordano-Attianese, G., Pule, M., Foster, A., Heslop, H., Rooney, C., Brenner, M., & Dotti, G. (2007) · Blood · doi:10.1182/blood-2007-02-072843 · Cited by 164
Self-citationAhmed, M. B., Hmida, N. B., Moes, N. D., Buyse, S., Abdeladhim, M., Louzir, H., & Cerf–Bensussan, N. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0801792 · Cited by 154
Huang, X., Guo, H., Kang, J., Choi, S., Zhou, T. C., Tammana, S., Lees, C. J., Li, Z.-Z., Milone, M. C., Levine, B. L., et al. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300404 · Cited by 146
Hsu, C., Jones, S. A., Cohen, C. J., Zheng, Z., Kerstann, K. W., Zhou, J., Robbins, P. F., Peng, P. D., Shen, X., Gomes, T. J., et al. (2007) · Blood · doi:10.1182/blood-2006-06-029173 · Cited by 112
Jensen, M. C., Tan, G., Forman, S. J., Wu, A. M., & Raubitschek, A. A. (1998) · Transplantation and Cellular Therapy · doi:10.1053/bbmt.1998.v4.pm9763110 · Cited by 100
Fifteen Years of Gene Therapy Based on Chimeric Antigen Receptors: “Are We Nearly There Yet?”
Dotti, G., Savoldo, B., & Brenner, M. K. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.142 · Cited by 94
Self-citationKim, Y., Dubey, P., Ray, P., Gambhir, S. S., & Witte, O. N. (2004) · Molecular Imaging and Biology · doi:10.1016/j.mibio.2004.06.009 · Cited by 66
Failed Adoptive Immunotherapy with Tumor-Specific T Cells
Roychowdhury, S., May, K. F., Tzou, K. S., Lin, T. Y., Bhatt, D., Freud, A. G., Guimond, M., Ferketich, A. K., Liu, Y., & Caligiuri, M. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1860 · Cited by 66
Hombach, A. A., Heuser, C., Sircar, R., Tillmann, T., Diehl, V., Pohl, C., & Abken, H. (1999) · Journal of Immunotherapy · doi:10.1097/00002371-199911000-00001 · Cited by 52
Cited by
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Liu, E., Marin, D., Banerjee, P., Macapinlac, H. A., Thompson, P., Basar, R., Nassif Kerbauy, L., Overman, B., Thall, P., Kaplan, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910607 · Cited by 2,217
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,472
Kochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D. E., Maric, I., Stetler-Stevenson, M., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2012) · Blood · doi:10.1182/blood-2011-10-384388 · Cited by 1,440
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 929
Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
Brudno, J. N., & Kochenderfer, J. N. (2019) · Blood Reviews · doi:10.1016/j.blre.2018.11.002 · Cited by 899
Metadata
- Authors
- Hoyos, V, Savoldo, B., Quintarelli, C., Mahendravada, A., Zhang, M., Vera, J., Heslop, H. E., Rooney, C. M., Brenner, M. K., & Dotti, G.
- Venue
- Leukemia
- Published
- 2010-04-29
- Volume
- 24
- Issue
- 6
- Pages
- 1160-1170
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2003197307
- Cited by
- 567
- References
- 48
- FWCI
- 9.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.